4.6 Review

Challenges and Opportunities With Oncology Drug Development in China

期刊

CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 105, 期 2, 页码 363-375

出版社

WILEY
DOI: 10.1002/cpt.1017

关键词

-

资金

  1. Bristol-Myers Squibb (BMS)

向作者/读者索取更多资源

Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have historically lagged behind those in the West, mainly the United States and Europe. China is currently undertaking regulatory reforms at a fast pace in order to mitigate this lag.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据